文献速递慢性静脉疾病

美国保险对大隐静脉和小隐静脉曲张腔内消融术的覆盖情况

American Insurance Coverage of Endovenous Ablation for Greater and Lesser Saphenous Varicose Veins.
PubMed 文献 · Ann Vasc Surg · 2024-07-17

该横断面分析评估了57份腔内激光/射频消融保险政策,其中36份(63.2%)覆盖该手术。覆盖指征共6种,最常见为瓣膜反流(n=29,80.6%),其中19份(52.8%)特别要求大隐静脉反流。高达33%的保险公司要求术前尝试保守治疗。

要点

  • 57份保险政策中36份(63.2%)覆盖腔内激光/射频消融。
  • 29份覆盖瓣膜反流的政策中19份(52.8%)特别要求大隐静脉反流。
  • 要求大隐静脉反流者显著多于其他类型瓣膜反流(52.8% vs 8.3%,P<0.001)。

核心结论

  • 保险政策对腔内激光/射频消融治疗曲张静脉的覆盖标准存在很大差异,尤其在瓣膜反流要求和保守治疗试验方面。

研究设计与样本

  • 横断面分析,基于最大州参保人数和市场份额选取57份腔内激光/射频消融保险政策,通过网页检索和电话访谈识别,从公开政策中提取医学必要标准。

主要发现

  • 57份保险政策中36份(63.2%)覆盖腔内射频或激光消融。
  • 覆盖指征共6种,最常见为瓣膜反流(n=29,80.6%)。
  • 29份覆盖瓣膜反流的公司中19份(52.8%)特别要求大隐静脉反流。
  • 要求大隐静脉反流者显著多于交界处反流(52.8% vs 8.3%,P<0.001)和非特异性反流(52.8% vs 16.7%,P<0.003)。
  • 高达33%的保险公司要求术前尝试保守治疗作为医学必要。

关键数值与推荐

  • 覆盖指征共6种,最常见为瓣膜反流(n=29,80.6%)。
  • 29份覆盖瓣膜反流的公司中19份(52.8%)特别要求大隐静脉反流。
  • 要求大隐静脉反流者显著多于交界处反流(52.8% vs 8.3%,P<0.001)和非特异性反流(52.8% vs 16.7%,P<0.003)。
  • 高达33%的保险公司要求术前尝试保守治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe cases of varicose veins can cause psychological distress as well as physical symptoms including skin discoloration, wounds, and burning sensations. One intervention, endovenous laser/radiofrequency ablation, is variably covered by insurance. Insurance coverage for this procedure was assessed for all indications of endovenous laser/radiofrequency ablation as medically necessity criteria. METHODS: A cross-sectional analysis was conducted of 57 insurance policies for endovenous laser/radiofrequency ablation. The insurance companies were selected based on the greatest state enrollment and market share. A web-based search and telephone interviews were utilized to identify the policies. Medically necessary criteria were then extracted from the publicly available policies. RESULTS: Fifty-seven (57) insurance policies were assessed, with 36 (63.2%) of these policies providing coverage for endovenous radiofrequency or laser ablation. Six indications existed for coverage, with the most common indication being the demonstration of valvular reflux (n = 29, 80.6%). Of the 29 companies that indicated coverage for valvular reflux, 19 (52.8%) specifically required saphenous reflux. Significantly more companies required saphenous reflux versus other specified types of valvular reflux (52.8% vs 8.3%, P < 0.001 for saphenous vs junctional reflux and 52.8% vs 16.7%, P < 0.003 for saphenous vs nonspecific). Prior to proceeding with endovenous laser or radiofrequency ablation, up to 33% of insurance companies required a trial of conservative management as medically necessary. CONCLUSIONS: There is a great discrepancy in insurance policy criteria for coverage of endovenous laser/radiofrequency ablation for the treatment of varicose veins, particularly regarding the requirements for valvular reflux and a trial of conservative therapy.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Onyima C, Hricz N, Zhu K, et al. American Insurance Coverage of Endovenous Ablation for Greater and Lesser Saphenous Varicose Veins. Ann Vasc Surg. 2024. PMID: 39029894. doi:10.1016/j.avsg.2024.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。